T Robak

Summary

Affiliation: University of Lodz
Country: Poland

Publications

  1. ncbi request reprint Current treatment options in prolymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Poland
    Med Sci Monit 13:RA69-80. 2007
  2. ncbi request reprint Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Poland
    Curr Pharm Des 18:3373-88. 2012
  3. ncbi request reprint Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies
    Tadeusz Robak
    Medical University of Lodz, Departments of Hematology and Dermatology, Ciołkowskiego 2 93 510 Lodz, Poland
    Expert Opin Investig Drugs 23:911-24. 2014
  4. pmc Application of new drugs in chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
    Mediterr J Hematol Infect Dis 2:e2010011. 2010
  5. pmc Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus
    Ewa Robak
    Department of Dermatology and Venerology, Medical University of Lodz, Krzemieniecka 5, 94 017 Lodz, Poland
    Mediators Inflamm 2006:17898. 2006
  6. ncbi request reprint Anti-CD37 antibodies for chronic lymphocytic leukemia
    Tadeusz Robak
    Medical University of Lodz, Department of Hematology, Ciołkowskiego 2, 93 510 Lodz, Poland
    Expert Opin Biol Ther 14:651-61. 2014
  7. doi request reprint Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
    Blood 120:3670-6. 2012
  8. doi request reprint BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 510 Lodz, Poland
    Int Rev Immunol 32:358-76. 2013
  9. doi request reprint The emerging therapeutic role of antibody mixtures
    Tadeusz Robak
    Medical University of Lodz, Department of Hematology, 93 510 Lodz, ul Ciołkowskiego 2, Poland 048 42 689 15 91 048 42 689 51 92
    Expert Opin Biol Ther 13:953-8. 2013
  10. ncbi request reprint JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms
    J Trelinski
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 510 Lodz, Ciolkowskiego 2, Poland
    Curr Med Chem 20:1147-61. 2013

Detail Information

Publications143 found, 100 shown here

  1. ncbi request reprint Current treatment options in prolymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Poland
    Med Sci Monit 13:RA69-80. 2007
    ..In this review, current therapeutic strategies in PLL are presented...
  2. ncbi request reprint Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Poland
    Curr Pharm Des 18:3373-88. 2012
    ..Clofarabine, nelarabine and forodesine need further investigation in rarer lymphid leukemias, to better define their status in the treatment of these disorders...
  3. ncbi request reprint Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies
    Tadeusz Robak
    Medical University of Lodz, Departments of Hematology and Dermatology, Ciołkowskiego 2 93 510 Lodz, Poland
    Expert Opin Investig Drugs 23:911-24. 2014
    ..In the near future, the addition of ADCs to the armamentarium of anticancer drugs should offer novel and more targeted treatment strategies. ..
  4. pmc Application of new drugs in chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
    Mediterr J Hematol Infect Dis 2:e2010011. 2010
    ..However, available therapies are only partially efficient and there is an obvious need to develop better strategies and new, more specific and active drugs...
  5. pmc Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus
    Ewa Robak
    Department of Dermatology and Venerology, Medical University of Lodz, Krzemieniecka 5, 94 017 Lodz, Poland
    Mediators Inflamm 2006:17898. 2006
    ..We also found a positive correlation of tMMP-9 and TIMP-1 with VEGF concentrations (rho = 0.450, P = .005 and rho = 0.387; P = .018, resp). tMMP-9, aMMP-9, and TIMP-1 serum levels are lower in SLE patients than in healthy control group...
  6. ncbi request reprint Anti-CD37 antibodies for chronic lymphocytic leukemia
    Tadeusz Robak
    Medical University of Lodz, Department of Hematology, Ciołkowskiego 2, 93 510 Lodz, Poland
    Expert Opin Biol Ther 14:651-61. 2014
    ..More recently, CD37, a member of the tetraspanin superfamily of cell surface antigens, has been considered as a target for B-cell malignancies...
  7. doi request reprint Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
    Blood 120:3670-6. 2012
    ..This trial is registered at www.clinicaltrials.gov as #NCT00718692...
  8. doi request reprint BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 510 Lodz, Poland
    Int Rev Immunol 32:358-76. 2013
    ..This article will review the preclinical rationale of BCR signaling inhibitors in the treatment of CLL, and the clinical evidence supporting the use of these agents in CLL patients. ..
  9. doi request reprint The emerging therapeutic role of antibody mixtures
    Tadeusz Robak
    Medical University of Lodz, Department of Hematology, 93 510 Lodz, ul Ciołkowskiego 2, Poland 048 42 689 15 91 048 42 689 51 92
    Expert Opin Biol Ther 13:953-8. 2013
    ..Recombinant antibody mixtures may be applicable to therapy of neoplastic, autoimmune and infectious diseases...
  10. ncbi request reprint JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms
    J Trelinski
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 510 Lodz, Ciolkowskiego 2, Poland
    Curr Med Chem 20:1147-61. 2013
    ..However, definitive data from ongoing and future preclinical and clinical trials will aid in better defining the status of these drugs in the treatment of these diseases...
  11. doi request reprint Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 510 Lodz, ul Ciolkowskiego 2, Poland and Copernicus Memorial Hospital, 93 510 Lodz, ul Ciolkowskiego 2, Poland
    Future Oncol 9:69-91. 2013
    ..Antibody-drug conjugates and recombinant immunotoxins are also being evaluated in lymphoid malignancies. Further studies will elucidate the role of these agents in the treatment of CLL...
  12. ncbi request reprint A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia
    P Robak
    Department of Experimental Hematology, Medical University of Lodz, Poland
    Curr Med Chem 19:5294-318. 2012
    ..This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL...
  13. doi request reprint Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders
    Tadeusz Robak
    Medical University of Lodz, Department of Hematology, Lodz, Poland
    Expert Opin Investig Drugs 21:921-47. 2012
    ....
  14. ncbi request reprint Editorial : novel and emerging drugs for leukemias
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 510 Lodz, ul Ciolkowskiego 2, Poland
    Curr Cancer Drug Targets 12:453-7. 2012
    ..Novel therapies are being evaluated both in preclinical studies and in early clinical trials. In this editorial, we demonstrate a brief review of the present insights into new therapeutic strategies for acute and chronic leukemias...
  15. doi request reprint Rituximab for chronic lymphocytic leukemia
    Tadeusz Robak
    Medical University of Lodz, Lodz, Poland
    Expert Opin Biol Ther 12:503-15. 2012
    ..Rituximab is a high-affinity chimeric mouse anti-CD20 monoclonal antibody, currently used for the treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and autoimmune disorders...
  16. ncbi request reprint Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity
    E Robak
    Department of Dermatology, Medical University of Lodz, 94 017 Lodz, Krzemieniecka 5 St, Poland
    Curr Med Chem 19:438-53. 2012
    ..Most of the new agents which could be potentially useful in the treatment of patients with SLE need further laboratory investigations and clinical trials. In this review, promising new agents, potentially useful in SLE, are presented...
  17. ncbi request reprint Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 510 Lodz, ul Ciołkowskiego 2, Poland
    Curr Cancer Drug Targets 8:156-71. 2008
    ..Finally, antiangiogenic mAbs, especially bevacimzumab, have a potential therapeutic role in this disease. In this review, new mAbs, potentially useful in CLL are presented...
  18. ncbi request reprint Emerging drugs for rarer chronic lymphoid leukemias
    Tadeusz Robak
    Medical University of Lodz, Copernicus Memorial Hospital, Department of Hematology, 93 510 Lodz, ul Ciołkowskiego 2, Poland
    Expert Opin Emerg Drugs 13:95-118. 2008
    ..Among these are prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) and its variants, large granular lymphocyte leukemia (LGLL) and adult T-cell leukemia/lymphoma (ATLL)...
  19. ncbi request reprint Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 513 Lodz, Pabianicka 62, Poland
    Recent Pat Anticancer Drug Discov 1:23-38. 2006
    ..The most important recent patents concerning oral formulations of 2-CdA have been presented...
  20. ncbi request reprint Recent progress in the management of chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
    Cancer Treat Rev 33:710-28. 2007
    ..Moreover, autologous and allogenic hematopoietic cell transplantations are increasingly considered for treatment of patients with CLL. In this review current therapeutic strategies in CLL are presented...
  21. ncbi request reprint Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
    Eur J Haematol 79:107-13. 2007
    ....
  22. ncbi request reprint Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 513 Lodz, Poland
    Blood 109:3672-5. 2007
    ..4%; 95% CI -4.3% to 7.0%; P = .64). In conclusion, HCL treatment with weekly 2-CdA infusions is equally effective but no safer than the standard 5-day 2-CdA protocol...
  23. ncbi request reprint Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Pabianicka 62, Lodz, Poland
    Curr Med Chem 13:3165-89. 2006
    ..This review will summarize current knowledge concerning the mechanism of action, pharmacological properties, clinical activity and toxicity of PNA accepted for use in clinical practice as well as new agents available for clinical trials...
  24. ncbi request reprint Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    Cancer 107:1542-50. 2006
    ..In vitro studies have shown synergistic or additive interactions between rituximab and purine nucleoside analogues. The results of recent clinical trials seem to confirm these preclinical observations...
  25. ncbi request reprint Current treatment options in hairy cell leukemia and hairy cell leukemia variant
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 510 Lodz, Ciołkowskiego 2, Poland
    Cancer Treat Rev 32:365-76. 2006
    ..In this review current therapeutic strategies in HCL and HCL-V are presented...
  26. ncbi request reprint New agents in chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 513 Lodz, Pabianicka 62, Poland
    Curr Treat Options Oncol 7:200-12. 2006
    ....
  27. ncbi request reprint Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Poland
    Blood 108:473-9. 2006
    ..No important differences in efficacy and toxicity were found between CC and 2-CdA regimens...
  28. ncbi request reprint Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, 93 513, Poland
    Drugs Aging 22:983-1012. 2005
    ..This review presents current results and treatment strategies with the use of PNAs in CLL, especially in elderly patients...
  29. ncbi request reprint Richter syndrome first manifesting as cutaneous B-cell lymphoma clonally distinct from primary B-cell chronic lymphocytic leukaemia
    E Robak
    Department of Dermatology, Medical University of Łódź, Łódź, Poland
    Br J Dermatol 153:833-7. 2005
    ..The patient was successfully treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) and adjuvant local radiotherapy...
  30. ncbi request reprint Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications
    T Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 513 Lodz, Pabianicka 62, Poland
    Curr Cancer Drug Targets 5:421-44. 2005
    ..Three other compounds: clofarabine, nelarabine and immucillin-H are currently being evaluated clinically...
  31. ncbi request reprint Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 513 Lodz, Pabianicka 62, Poland
    Rev Recent Clin Trials 1:15-34. 2006
    ..This review article will summarize the results of recent clinical trials with 2-CdA in hematological malignancies, multiple sclerosis and other autoimmune diseases...
  32. doi request reprint Alemtuzumab for B-cell chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 510 Lodz, ul Ciolkowskiego 2, Poland
    Expert Rev Anticancer Ther 8:1033-51. 2008
    ..Moreover, the European Commission recently granted marketing authorization to alemtuzumab for the treatment of patients with B-CLL for whom fludarabine combination monotherapy is not appropriate...
  33. doi request reprint New nucleoside analogs for patients with hematological malignancies
    Tadeusz Robak
    Medical University of Lodz, Department of Hematology, Lodz, Poland
    Expert Opin Investig Drugs 20:343-59. 2011
    ..In the last few years, several new purine and pyrimidine nucleoside analogs have been synthesized and made available for both preclinical studies and clinical trials...
  34. ncbi request reprint Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 510 Lodz, ul Ciołkowskiego 2, Poland
    Curr Med Chem 18:638-66. 2011
    ..This article reviews the various classes of AML targets and drugs that are under early phase clinical evaluation, especially those that are likely to enter clinical practice in the near future...
  35. doi request reprint New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    BioDrugs 25:13-25. 2011
    ..In this article we review data on new anti-CD20 mAbs that are potentially useful in the treatment of lymphoid malignancies...
  36. doi request reprint Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 510 Lodz, ul Ciołkowskiego 2, Poland
    Expert Rev Anticancer Ther 10:1529-43. 2010
    ..Recently, several new anti-CD20 monoclonal antibodies have been developed and are now being evaluated in clinical trials...
  37. doi request reprint Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Poland
    Hematology 15:351-9. 2010
    ..octagam 10% was well tolerated and effective in this population representative of adult patients with ITP, even at the maximum infusion rate of 0·12 ml/kg/minute, without unexpected safety issues...
  38. doi request reprint Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 510 Lodz, ul Ciolkowskiego 2, Poland
    Cancer Treat Rev 37:3-10. 2011
    ..As with HCl-V, patients with HCl-JV have leukocytosis, weak TRAP activity in leukemic cells, and lack of CD25 antigen. In this review, the biology, diagnostic criteria, and current therapeutic options in HCl-V and HCl-JV are presented...
  39. doi request reprint Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 510 Lodz, ul Ciołkowskiego 2, Poland
    J Clin Oncol 28:1863-9. 2010
    ..Both combinations have unsatisfactory activity in patients with 17p13 (TP53 gene) deletion...
  40. doi request reprint Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Ciolkowskiego 2, Lodz, Poland 93 510
    J Clin Oncol 28:1756-65. 2010
    ..This trial was designed to compare chemoimmunotherapy with chemotherapy alone in patients with previously treated CLL...
  41. doi request reprint Current and emerging therapies for acute myeloid leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    Clin Ther 31:2349-70. 2009
    ..The incidence of AML increases with age, and older patients typically have worse treatment outcomes than do younger patients...
  42. ncbi request reprint TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies
    Tadeusz Robak
    Medical University of Lodz, Copernicus Memorial Hospital, Department of Hematology, 93 510 Lodz, Ciołkowskiego 2, Poland
    Curr Opin Investig Drugs 10:1383-90. 2009
    ..1 mg/kg. TRU-016 is a promising therapeutic agent for patients with B-cell lymphoid malignancies, especially patients refractory to standard treatment...
  43. doi request reprint Current and emerging treatments for chronic lymphocytic leukaemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lode, Copernicus Memorial Hospital, Lodz, Poland
    Drugs 69:2415-49. 2009
    ..However, the exact role of HSCT, autologous or allogeneic, in the standard management of CLL patients is still undefined...
  44. ncbi request reprint Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 510 Lodz, ul Ciołkowskiego 2, Poland
    Curr Med Chem 16:2212-34. 2009
    ..This review will focus on agents currently being explored in preclinical studies and in early clinical trials...
  45. ncbi request reprint GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies
    Tadeusz Robak
    Medical University of Lodz and Copernicus Memorial Hospital, Department of Hematology, 93 510 Lodz, Ciolkowskiego 2, Poland
    Curr Opin Investig Drugs 10:588-96. 2009
    ..Based on preclinical and preliminary clinical data, GA-101 appears to be a promising therapeutic agent for CD20-positive B-cell lymphoid malignances, including non-Hodgkin lymphomas and chronic lymphocytic leukemia...
  46. doi request reprint Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 510 Lodz, Ciolkowskiego 2 Str, Poland
    Molecules 14:1183-226. 2009
    ..This review will summarize current knowledge concerning the mechanism of action, pharmacologic properties, clinical activity and toxicity of PNAs accepted for use in clinical practice, as well as new agents available for clinical trials...
  47. doi request reprint Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus
    E Robak
    Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland
    Lupus 18:332-41. 2009
    ..These data may suggest that angiogenic process is involved in the pathogenesis of this disease...
  48. doi request reprint Management of hairy cell leukemia variant
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
    Leuk Lymphoma 52:53-6. 2011
    ..Currently, immunochemotherapy with rituximab and purine nucleoside analogs (PNAs) should be considered as the treatment of choice in previously untreated patients...
  49. doi request reprint Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    Cancer 115:94-100. 2009
    ..The results of this study have demonstrated that the cladribine and cyclophosphamide regimen may improve treatment results in this poor-risk patient population...
  50. ncbi request reprint A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Po
    A Wrzesien-Kus
    Department of Hematology, Medical University of Lodz, ul Pabianicka 62, 93 513, Lodz, Poland
    Ann Hematol 84:557-64. 2005
    ..We conclude that CLAG-M regimen has significant antileukemia activity in refractory AML, which seems to be better than the activity of many other regimens. The toxicity of the treatment is acceptable...
  51. ncbi request reprint Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Blood 96:2723-9. 2000
    ..The probability of overall survival calculated from Kaplan-Meier curves at 24 months was also similar for both groups (78% and 82%, respectively). (Blood. 2000;96:2723-2729)..
  52. ncbi request reprint Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Leuk Lymphoma 39:121-9. 2000
    ..5x10(9) G/l was 18.7 days and platelets>50x10(9)/l was 27.2 days. In conclusion, the CLAG regimen had significant antileukemic activity and acceptable toxicity as reinduction treatment in refractory or relapsed AML patients...
  53. ncbi request reprint Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine
    T Robak
    Department of Haematology, Medical University of Łódź and Copernicus Memorial Hospital, Pabianicka 62, 93 513, ul Pabianicka 62, Łódź, Poland
    Eur J Cancer 40:383-9. 2004
    ..However, further studies are necessary to establish the real risk of lung cancer in CLL patients treated with 2-CdA...
  54. ncbi request reprint Low-grade non-Hodgkin's lymphoma in a patient with systemic lupus erythematosus
    T Robak
    Department of Hematology Medical University of Lodz, Copernicus Memorial Hospital, Poland
    Leuk Lymphoma 41:659-67. 2001
    ..The SLE responded well to treatment with prednisone and the course of the LGNHL was stable and cytotoxic treatment was not required...
  55. ncbi request reprint 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Eur J Haematol 62:49-56. 1999
    ..The results of our study indicate that a 2-h infusion of 2-CdA in HCL patients is at least as effective as a 24-h infusion but more convenient to the patients, and may be given on an outpatient basis...
  56. ncbi request reprint Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 513 Lodz, ul Pabianicka 62, Poland
    Eur J Haematol 66:188-94. 2001
    ..Whether a combination of 2-CdA with cyclophosphamide and mitoxantrone would result in improved outcome as compared to 2-CdA alone, is being investigated in a prospective, randomised trial...
  57. ncbi request reprint Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity
    E Robak
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, 93 513 Lodz, Pabianicka 62 st, Poland
    Eur Cytokine Netw 12:445-52. 2001
    ..252, p = 0.05). In conclusion, serum levels of the angiogenic factors HGF and VEGF may be relevant in SLE pathogenesis. Their concentrations seem to be markers of SLE activity...
  58. ncbi request reprint Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients
    T Robak
    Department of Haematology, Medical University of Lodz, Institute of Haematology and Blood Transfusion, Warsaw, Poland
    Br J Haematol 108:357-68. 2000
    ..4%) pretreated and 74 (38.1%) untreated patients (P = 0.03), were the most frequent toxic effects. Our results indicate that 2-CdA is an effective, relatively well-tolerated drug, especially in previously untreated CLL...
  59. ncbi request reprint Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG)
    A Wrzesien-Kus
    Department of Hematology, Medical University of Lodz, ul Pabianicka 62, 93 513 Lodz, Poland
    Ann Hematol 85:366-73. 2006
    ..We have shown that additional karyotype abnormalities did not influence the clinical characteristics of the patients; however, their influence on treatment results needs to be further assessed...
  60. ncbi request reprint Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies
    T Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Poland
    Chemotherapy 51:247-51. 2005
    ..Seven out of 20 patients (35%) responded, including one complete response. Median overall survival time of responding patients was 22 months (range 3-30). Myelosuppression and infections were the major toxicity of the EC regimen...
  61. ncbi request reprint Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): an unusual variant of Richter's syndrome
    T Robak
    Department of Hematology and Department of Oncology, Medical University of Lodz, Poland
    Eur J Haematol 67:322-7. 2001
    ..Overall survival with current strategies is poor, and further insight into the natural history, biology, and treatment of PBL are needed...
  62. ncbi request reprint Richter's syndrome following cladribine therapy for chronic lymphocytic leukemia first manifested as pathologic fracture of the femur
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Leuk Lymphoma 42:789-96. 2001
    ..RS was first manifested as a pathologic fracture of the left femur. The LBCL was clonally distinct from the original CLL cells. The patient was successfully treated with CHOP and radiotherapy and obtained complete response of the LBCL...
  63. ncbi request reprint A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG)
    A Wrzesien-Kus
    Department of Hematology, Medical University, Łódź, Poland
    Eur J Haematol 71:155-62. 2003
    ....
  64. ncbi request reprint Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Poland
    Leuk Lymphoma 41:545-57. 2001
    ..4). We suggest that intensive treatment with HDChl as first line and 2-CdA as second line should be applied in more advanced rather than in less advanced stages of CLL until the final results of randomized clinical trials are available...
  65. ncbi request reprint The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study
    A Wrzesien-Kus
    Department of Hematology, Medical University of Lodz, Poland
    Neoplasma 49:405-11. 2002
    ..The hematological toxicity of this treatment seems to be comparable with "3+7" regimen...
  66. ncbi request reprint Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Pabianicka 62 str, 93 513 Lodz, Poland
    Ann Hematol 83:225-31. 2004
    ..ALL of the elderly is a rare disease with poor prognosis. Further clinical trials evaluating the disease features, outcome, and new therapeutic approaches are warranted...
  67. ncbi request reprint Primary cutaneous marginal zone B-cell lymphoma in a patient with chronic lymphocytic leukaemia
    E Robak
    Department of Dermatology, Medical University of Łódź, Łódź, Poland
    Br J Dermatol 157:591-5. 2007
    ..In contrast, a 13q deletion was found in BM and PB CLL cells. The patient was treated with chlorambucil and complete response of PCMZL was achieved. To our knowledge this is the first patient with CLL in whom PCMZL has been diagnosed...
  68. ncbi request reprint Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia
    T Robak
    Department of Hematology, Medical University, , Poland
    Leukemia 15:1510-6. 2001
    ..However, toxicity, especially after CMC5 administration, is significant. Therefore, we recommend the CMC3 but not the CMC5 programme for further evaluation...
  69. ncbi request reprint Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells
    Paweł Robak
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    Leuk Lymphoma 47:2625-34. 2006
    ..The SDX-101 plus ALT combination resulted in only sub-additive cytotoxicity (CI = 1.25). In conclusion, these data obtained in vitro indicate that addition of 2-CdA, FA or RIT to SDX-101 significantly enhance cytotoxicity in B-CLL cells...
  70. ncbi request reprint Alemtuzumab in the treatment of chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz 93 513, Poland
    BioDrugs 19:9-22. 2005
    ..Moreover, antiviral and antibacterial prophylaxis is mandatory...
  71. pmc Lymphocyctes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity
    E Robak
    Department of Dermatology and Venereology, , Poland
    Mediators Inflamm 10:179-89. 2001
    ....
  72. pmc Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus
    E Robak
    Department of Dermatology and Venereology, Medical University of Łódź, 94 513 Lódź, ul Krzemiemiecka 5, Poland
    Mediators Inflamm 13:171-80. 2004
    ..The association between dendritic cell number and clinical features seems to be less clear...
  73. ncbi request reprint Distribution and clinical significance of blood dendritic cells in children with juvenile idiopathic arthritis
    E Smolewska
    Department of Paediatric Cardiology, Medical University of Lodz, Sporna 36 50, 91 738 Lodz, Poland
    Ann Rheum Dis 67:762-8. 2008
    ..A role for dendritic cells (DC) in the development of adult rheumatoid arthritis has been suggested. To date, this problem has been poorly explored in juvenile idiopathic arthritis (JIA)...
  74. pmc Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, Poland
    Mediators Inflamm 8:277-86. 1999
    ..423; P<0.001). In addition, sIL-6R and OSM serum concentrations correlated also with CLL Rai stage. In conclusion, the serum level of IL-6, OSM and sIL-6R, but not LIF and sgp130, are useful indicators of CLL activity...
  75. ncbi request reprint Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    Leukemia 16:1015-27. 2002
    ..NA should be routinely used as second line treatment and possibly as first line therapy in younger patients, who are candidates for potentially curative treatment such as stem cell transplantation and/or monoclonal antibodies...
  76. ncbi request reprint Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem
    Agnieszka Wierzbowska
    Department of Hematology, Medical University, Lodz, Poland
    Eur J Haematol 80:115-26. 2008
    ..In the current report, we present the final results of multi-center phase II study evaluating the efficacy and toxicity of CLAG-M salvage regimen in poor risk refractory/relapsed AML patients...
  77. doi request reprint Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group
    Ewa Kalinka-Warzocha
    Department of Proliferative Diseases, Regional Oncology Center, Lodz, Poland
    Cancer 113:367-75. 2008
    ....
  78. ncbi request reprint Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 513 Lodz, Pabianicka 62, Poland
    Leuk Lymphoma 45:937-44. 2004
    ..This regimen can be considered as an alternative treatment of CD-20 positive indolent lymphoproliferative disorders...
  79. ncbi request reprint Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 513 Lodz, Poland
    Neoplasma 50:172-5. 2003
    ..5 and 4 months, p=0.003 and p=0.008, respectively). Low-dose melphalan shows significant activity in high-risk MDS and AML with multilineage dysplasia with acceptable toxicity...
  80. ncbi request reprint Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus
    E Robak
    Department of Dermatology and Venereology, Medical University of Lodz, Poland
    Lupus 11:348-55. 2002
    ..04). In contrast, the correlation between bFGF and endostatin was significantly negative (p = - 0.299, P < 0.04). In conclusion, serum levels of the angiogenic and antiangiogenic factors may play an important role in SLE pathogenesis...
  81. doi request reprint R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis
    Małgorzata Rogalińska
    Department of Cytobiochemisty, University of Lodz, Lodz, Poland
    J Cell Biochem 109:217-35. 2010
    ..Marked between-patient differences in expression patterns of apoptosis-regulating factors in CLL cells were observed, explaining the variations in patients' sensitivity to therapy...
  82. ncbi request reprint Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment
    Tadeusz Robak
    Department of Hematology, Medical University of Łódź, Poland
    Eur J Haematol 69:27-36. 2002
    ..However, since the second response is usually shorter and myelotoxicity more pronounced than during the first therapy, more clinical trials to find other therapeutical approaches are necessary...
  83. ncbi request reprint Relation of P-glycoprotein expression with spontaneous in vitro apoptosis in B-cell chronic lymphocytic leukemia
    K Jamroziak
    Department of Hematology, Medical University of Lodz, 93 513, Poland
    Neoplasma 51:181-7. 2004
    ..The difference in the rates of spontaneous apoptosis among male and female patients may contribute to gender-dependent variations in clinical outcome in B-CLL...
  84. ncbi request reprint Atypical chronic myelogenous leukemia following immunosuppressive therapy for severe aplastic anemia
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Leuk Lymphoma 35:193-9. 1999
    ..This case of atypical, secondary CML was refractory to treatment with interferon alpha and hydroxyurea...
  85. ncbi request reprint Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia
    A Szmigielska-Kaplon
    Department of Hematology, Medical University of Łódź, Poland
    Ann Hematol 81:508-13. 2002
    ..High sensitivity of B-CLL cells to IDA suggests the possibility of lowering its dose in patients, especially when combined with 2-CdA...
  86. ncbi request reprint Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells
    Piotr Smolewski
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital Lodz, Poland
    Leuk Lymphoma 46:87-100. 2005
    ..ALT and PNA or RTX trigger complementary changes in expression of proteins regulating cell propensity to undergo apoptosis, what provides molecular rationale for combining ALT with those agents...
  87. ncbi request reprint The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro
    Anna Korycka
    Department of Haematology, Medical University of Lodz, Copernicus Memorial Hospital, 62 Pabianicka Str, 93 513 Lodz, Poland
    Leuk Lymphoma 44:1549-55. 2003
    ..However, further experimental and clinical studies concerning the usefulness of these combinations in the treatment of CML patients seem warranted...
  88. ncbi request reprint Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro
    Anna Szmigielska-Kaplon
    Department of Hematology, Medical University of Łódź, 93 513 Łódź, ul Pabianicka 62, Poland
    Eur J Haematol 68:370-5. 2002
    ..It failed however to point the best one to be combined with cladribine. We suggests that further clinical trials with such combinations are needed...
  89. doi request reprint Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG)
    Ewa Lech-Maranda
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, Ciolkowskiego 2 Str, 93 510 Lodz, Poland
    Int J Infect Dis 14:e132-40. 2010
    ..The goal of this study was to determine the effect of this modification on the incidence and spectrum of infectious complications...
  90. ncbi request reprint Novel systemic drugs for cutaneous T-cell lymphoma
    Ewa Lech-Maranda
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 513 Lodz, Ciolkowskiego 2, Poland
    Recent Pat Anticancer Drug Discov 6:70-93. 2011
    ..This review focuses on recent advances in the development of systemic agents for CTCL including both novel patented compounds and novel therapeutic protocol of intervention...
  91. ncbi request reprint The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro
    Anna Korycka
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    Eur J Haematol 73:418-26. 2004
    ..However, further experimental studies on the usefulness of these combinations in the treatment of myeloid leukemia patients are warranted...
  92. ncbi request reprint Skin lesions in chronic lymphocytic leukemia
    Ewa Robak
    Department of Dermatology and Venereology, Medical University of Lodz, Poland
    Leuk Lymphoma 48:855-65. 2007
    ..Other secondary lesions present as vasculitis, purpura, generalized pruritus, exfoliative erythroderma, and paraneoplastic pemphigus. An exaggerated reaction to an insect bite and insect bite-like reactions have been also observed...
  93. ncbi request reprint Expression of gene encoding P65 oncofetal protein in acute and chronic leukemias
    E Balcerczak
    Department of Pharmaceutical Biochemistry, Molecular Biology Laboratory Medical University, Lodz, 90 151 Poland
    Neoplasma 49:295-9. 2002
    ..No relationship between the expression of p65 gene and clinical stage of leukemia was observed. The lower percentage of positivity (presence of gene transcript) was seen in patients with ALL (42%) and AML (46%)...
  94. ncbi request reprint Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia
    J Gora-Tybor
    Department of Hematology Medical University of Lodz, Lodz, 93 513 Poland
    Neoplasma 49:145-8. 2002
    ..The level of these factors might correlate with the activity of the disease...
  95. ncbi request reprint Cladribine in the treatment of chronic lymphocytic leukemia
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, Poland
    Leuk Lymphoma 40:551-64. 2001
    ..We suggest, that in patients with CLL, 2-CdA should be used as second line treatment rather than the first line therapy until the final results of ongoing randomized clinical trials are available...
  96. ncbi request reprint Altered expression of nuclear non-histone protein (p44/46) in different stages of B-chronic lymphocytic leukemia
    Z M Kiliańska
    Department of Cytobiochemistry, S Banacha 12 16, University of Lodz, Poland
    Leuk Lymphoma 41:635-42. 2001
    ..The expression of this particular nuclear protein seems to correlate with the progression of the leukemia...
  97. ncbi request reprint Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Neoplasma 47:168-71. 2000
    ..These results may indicate that routine addition of corticosteroids to purine analogs in the treatment of lymphoid malignancies is not warranted...
  98. ncbi request reprint Influence of 2-chlorodeoxyadenosine (cladribine) on human erythrocytes
    A Marczak
    Department of Thermobiology, University of Łødź, Poland
    Int J Biochem Cell Biol 36:1645-54. 2004
    ..However, the higher concentrations of 2-CdA (about 5 microg/ml) can be also toxic to erythrocytes...
  99. doi request reprint Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura
    T Robak
    Department of Hematology, Medical University of Lodz, 2, Ciolkowskiego str, Lodz 93 510, Poland
    Hematology 14:227-36. 2009
    ..Thus, in patients with chronic ITP, a two-day regimen of Privigen was effective in increasing platelet count, reducing bleeding events and was well tolerated...
  100. ncbi request reprint 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Leuk Lymphoma 34:151-7. 1999
    ..In conclusion, our results suggest that 2-CdA is also effective treatment for elderly patients with CLL. The drug toxicity is acceptable and seems to be similar for that observed in younger patients...
  101. ncbi request reprint The search for optimal treatment in relapsed and refractory acute myeloid leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, Poland
    Leuk Lymphoma 43:281-91. 2002
    ..New cytotoxic drugs, agents with novel mechanisms of action, and new treatment strategies are currently being investigated. The management of refractory or relapsed AML patients is reviewed in this study...